DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group L — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group L maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group l is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
VRK serine/threonine kinase 2 (VRK2) — VRK2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sindrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2V62 · 1.7 Å · ligand SUCCINIC ACID (SIN). Experimental structure, not a prediction.
What the evidence adds up to
A 1999 study reported that the FANCG protein, encoded by the gene mutated in Fanconi anemia complementation group G, forms a physical complex with the FANCA protein in both cytoplasm and nucleus. Endogenous FANCA/FANCG complex was detected in non-FA cells and in FA cells from groups D and E, but no complex was detected in cell lines from groups A and G, and reduced levels were found in groups B, C, F, and H. Wild-type levels of the complex were restored upon correction of the cellular phenotype by transfection or cell fusion. The authors proposed that the cellular FA phenotype could be connected to three biochemical subtypes based on levels of this complex, and that disruption of the complex might provide a strategy for chemosensitisation of neoplastic cells.
A 1999 review described Fanconi anemia as a rare autosomal recessive disease with multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. It stated that the mean age of onset of anaemia is 8 years, and the mean survival is 16 years, with death usually resulting from complications of bone marrow failure. The review noted that three Fanconi anemia genes had recently been identified and cloned, and described the encoded proteins as part of a cellular pathway controlling chromosome stability.
A 2018 report described successful haematopoietic cell transplantation in three Fanconi anemia patients with renal impairment using an ultra-reduced conditioning regimen of cyclophosphamide and fludarabine. The authors noted that doses of alkylating agents in conditioning are usually significantly decreased due to genomic instability of FA cells, and that renal impairment requires further modification to avoid additional toxicity. No sample sizes beyond three patients were given, and no survival or response rates were reported.
No drug has been tested in a clinical trial for Fanconi anemia complementation group L specifically. What is missing is any trial that stratifies patients by complementation group, any funding for such a trial, and any evidence that the biochemical findings from 1999 have been translated into a treatment for any FA subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Proceedings of the National Academy of Sciences · 1999 · 155 citations · open access
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA
AbstractFanconi anemia (FA) is a recessively inherited disease characterized at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to cross-linking agents. FA is genetically heterogeneous, comprising at least eight complementation groups (A-H). We report that the protein encoded by the gene mutated in complementation group G (FANCG) localizes to the cytoplasm and nucleus of the cell and assembles in a molecular complex with the FANCA protein, both in vivo and in vitro. Endogenous FANCA/FANCG complex was detected in both non-FA cells and in FA cells from groups D and E. By contrast, no complex was detected in specific cell lines belonging to groups A and G, whereas reduced levels were found in cells from groups B, C, F, and H. Wild-type levels of FANCA/FANCG complex were restored upon correction of the cellular phenotype by transfection or cell fusion experiments, suggesting that this complex is of functional significance in the FA pathway. These results indicate that the cellular FA phenotype can be connected to three biochemical subtypes based on the levels of FANCA/FANCG complex. Disruption of the complex may provide an experimental strategy for chemosensitization of neoplastic cells.
Current Opinion in Hematology · 1999 · 33 citations
The molecular and cellular biology of Fanconi anemia
AbstractFanconi anemia is a rare autosomal recessive disease characterized by multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. The mean age of onset of anemia is 8 years, and the mean survival is 16 years. Death usually results from complications of bone marrow failure. Considerable progress in Fanconi anemia research has resulted from the recent identification and cloning of three Fanconi anemia genes. The current review describes the structure and function of the Fanconi anemia genes and describes the role of the encoded Fanconi anemia proteins in a cellular pathway controlling chromosome stability.
South African Medical Journal · 2018 · 9 citations · open access
Fanconi anaemia in South Africa: Past, present and future
AbstractFanconi anaemia (FA) is an inherited genetic disorder characterised by somatic anomalies, bone marrow failure and an increased predisposition to solid tumours and haematological malignancies. South African (SA) black and Afrikaner individuals are at higher than average risk for this condition owing to genetic founder mutations in certain Fanconi-associated genes. This review explores the epidemiology, clinical presentation, diagnostic modalities and recommended care of affected patients, focusing on the founder population groups in SA. The early diagnosis of FA is important and provides improved opportunities for early intervention, but remains challenging.
Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using ultra‐reduced doses of cyclophosphamide and fludarabine
AbstractHematopoietic cell transplantation (HCT) remains until now the only curative modality for hematological manifestations in patients with Fanconi anemia (FA). The doses of alkylating agents used in the conditioning of this patient population before HCT are usually significantly decreased due to the genomic instability of the FA cells. FA patients with renal impairment represent a dilemma because of the need to further modify the conditioning regimen according to the degree of renal impairment to avoid additional toxicity. At our institution, we successfully transplanted three FA patients using an ultra-modified regimen.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
